Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by
cognitive dysfunction and synaptic failure. The current therapeutic approaches are mainly …

The study of Alzheimer's Disease (AD) has traditionally focused on neuropathological
mechanisms that has guided therapies that attenuate neuropathological features. A new …

Mouse models of human diseases are invaluable tools for studying pathogenic mechanisms
and testing interventions and therapeutics. For disorders such as Alzheimer's disease in …

Neuronal endosomal dysfunction, the earliest known pathobiology specific to Alzheimer's
disease (AD), is mediated by the aberrant activation of Rab5 triggered by APP-β secretase …

Research demonstrates that the neural mechanisms underlying synaptic plasticity and
learning and memory involve mobilization of AMPA‐type neurotransmitter receptors at …

Neuronal aging increases the risk of late-onset Alzheimer's disease. During normal aging,
synapses decline, and β-amyloid (Aβ) accumulates intraneuronally. However, little is known …

It is well established that GluA1 mediated synaptic plasticity plays a central role in the early
development of AD. The complex cellular and molecular mechanisms that enable GluA1 …

Pathogenic processes underlying Alzheimer's disease (AD) affect synaptic function from
initial asymptomatic stages, long time before the onset of cognitive decline and …

Degeneration of synapses in Alzheimer's disease (AD) strongly correlates with cognitive
decline, and synaptic pathology contributes to disease pathophysiology. We recently …

Alzheimer's disease (AD) is a progressive neurodegenerative disease that is the most
common cause of dementia. Symptoms of AD include memory loss, disorientation, mood …